Mallinckrodt is a post-confirmation case: the operating restructuring has been implemented, but the docket remains active around trust administration, opioid-abatement reporting, and continued reconciliation of general unsecured claims. The 2020 case began as a litigation-driven balance-sheet restructuring, with the company citing more than 3,000 opioid lawsuits, Acthar-related disputes, more than $100 million of defense costs since 2017, and roughly $5.283 billion of funded debt, including first-lien bank debt, secured notes, and unsecured notes, in the Welch first-day declarationDkt. 128. That first restructuring was built around a proposed $1.6 billion opioid settlement, a $260 million DOJ Acthar settlement, support from a large majority of unsecured noteholders, and a plan architecture intended to preserve operations while channeling litigation recoveries and creditor distributions through settlement and trust structures.
The company returned to chapter 11 in August 2023 after the 2022 emergence left it facing a tighter capital structure than its business could support. The second filing was precipitated by $817 million of 2025 maturities, projected negative free cash flow through 2026, rising floating-rate interest expense, Acthar and Therakos underperformance, and deteriorating market values for the company’s debt and equity; the debtors entered chapter 11 with an RSA supported by approximately 88% of first-lien funded debt and 86% of second-lien funded debt, targeting a reduction of secured funded debt from $3.6 billion to $1.75 billion and a reduction of remaining opioid settlement obligations to a prepaid $250 million amount, as described in the . The 2023 proceeding moved quickly on a prepackaged path: Mallinckrodt filed the , the court approved the disclosure statement and confirmed that plan on October 10, 2023 through the , and the company later filed exit financing documents in the .
The live case posture is now administrative rather than operational distress. Mallinckrodt’s latest post-confirmation report says the plan from the 2020 case was confirmed on March 2, 2022 and became effective on June 16, 2022, with $7.8 million of cash disbursements during the quarter ended March 31, 2026 and $247.5 million transferred since the effective date; it also reports 100% payment of administrative, secured, and priority claims, but only 1% paid on roughly $1.94 billion of allowed general unsecured claims, and no final decree date yet, in the quarterly post-confirmation reportDkt. 9359. The creditor-trust work remains active: the court recently sustained part of the General Unsecured Claims Trustee’s tenth omnibus objection, disallowing three duplicative General Dynamics-Ordnance & Tactical Systems claims while preserving the surviving claim and certain non-debtor carve-outs, through the second omnibus objection orderDkt. 9366.
Near-term activity is concentrated in claim reconciliation and trust reporting. The General Unsecured Claims Trustee is seeking to extend the claims objection deadline from September 11, 2026 to June 11, 2027, with objections to that motion due June 11, 2026, in the eighth claims-objection deadline extension motionDkt. 9367. Separately, the opioid trusts continue to report on abatement funding and distributions: the National Opioid Abatement Trust II reported $24.5 million of CVR funding received in November 2025 and $29.2 million of opioid claims paid during 2025 in its annual opioid-abatement reportDkt. 9364, while the Tribal Abatement Fund Trust II reported funding from Opioid MDT II, pending litigation interests, and compliance-driven withholding of some tribal distributions in its annual tribal abatement reportDkt. 9361.
